Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | CFTR | P13569 | 15/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PROC | P04070 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455832 | 1.00 | LMNA (0.74) | LMNAPKMCFTRMEN1MAPT | |
| SCHEMBL6451591 | 0.78 | GAA (0.72) | KMT2A | |
| SCHEMBL6459743 | 0.78 | GAA (0.72) | KMT2A | |
| SCHEMBL3922223 | 0.74 | CFTR (0.69) | LMNAPKMCFTR | |
| SCHEMBL6455851 | 0.74 | GAA (0.43) | LMNAPKMKMT2A | |
| SCHEMBL3933163 | 0.73 | CFTR (0.82) | CFTR | |
| SCHEMBL3922221 | 0.72 | CFTR (0.76) | CFTR | |
| SCHEMBL12518071 | 0.71 | LMNA (0.61) | LMNAPKMCFTRMEN1MAPT | |
| SCHEMBL10119262 | 0.71 | LMNA (0.61) | LMNAPKMCFTRMEN1MAPT | |
| SCHEMBL8495772 | 0.70 | LMNA (0.61) | LMNAPKMCFTRMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | POWERS GORDON D (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | RNASEH1, RNASEL, RNASE1 | LMNA 765/4885PKM 2084/4885CFTR 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.